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228 Pulmonary and nutritional outcomes in children with cystic
ﬁbrosis diagnosed by meconium ileus in Argentina
V. D’Alessandro1, F. Renteria1, E. Segal1, G. Diez1. 1Children’s Hospital ‘Sor
Marı´a Ludovica’ Pulmonary, La Plata, Argentina
Introduction: Early diagnosis in Cystic Fibrosis (CF) still remains a challenge,
because it allows the implementation of appropriate therapeutic strategies. It can
reach through neonatal screening (NS) an early detection or by meconium ileus a
premature clinical manifestation associated with poorer growth.
Objective: To compare clinical status and lung function in children with CF
diagnosed with meconium ileus and those detected by NS.
Methods: We compare two groups: one detected by NS and one diagnosed by
meconium ileus (MI) since 1995 (beginning of the program of NS in the state of
Buenos Aires). We assessed: Z score Weight/age, Z score Height/age from 6 months
up to 6 years of age, Forced Expiratory Volume in 1st (FEV1). We also registered
ﬁrst isolation of Pseudomonas aeruginosa (Pa). Student’s t-test was performed to
compare the means of the indicators.
Results: We included 26 patients in NS group and 31 in MI, all with pancreatic in-
sufﬁciency. p.PHE508del/p.PHE508del was present in 52% of NS and 41.4% in MI.
In MI group were four deaths and one in NS. The NS group showed better nutritional
parameters than MI, as seen in the table. We found no signiﬁcant differences in
ﬁrst isolation of Pa (p = 0.55) and FEV1 (p = 0.11) between the two groups.
Table: Nutritional parameters in NS and MI groups
Z score
6 months* 1 year* 3 years 6 years
W/A H/A W/A H/A W/A H/A W/A H/A
NS −0.53 −0.77 −0.52 −0.62 0.28 0.22 0.27 0.25
MI −1.63 −1.85 −1.33 −1.77 −0.60 −0.50 −0.62 −0.68
*p= 0.05.
Conclusion: Although the results suggest better nutritional status and lung function
in the NS group, advances in non surgical techniques as well as nutritional support
have achieved better growth parameters within the MI group.
229 Prucalopride: a review of the ﬁrst 12 months of use
K. Williams1, S. Huntington1, N. Shaw1, S.P. Conway1, D. Peckham2. 1St James
University Hospital, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom;
2St James University Hospital, Adult CF Unit, Leeds, United Kingdom
Objectives: Constipation is common in CF. In 2010 NICE recommended prucalopride,
a selective serotonin receptor agonist, for the treatment of chronic constipation in
women who had failed conventional therapy. Patients with severe lung disease were
excluded from pivotal trials.
Methods: Data were retrospectively collected from patient records. Laxative treatment
and admission frequency were compared pre and post prucalopride. Side-effects and
patients’ perceptions were noted.
Results: Four pancreatic-insufﬁcient females with a history of refractory constipa-
tion/DIOS were commenced on oral prucalopride (Table 1).
Table 1. Patient demographics
Patient (age [yrs]) Genetics FEV1 (% predicted) BMI Diabetic
1 (28) DF508/DF508 59 23.8 No
2 (31) DF508/DF508 37 19.8 Yes
3 (38) DF508/DF508 33 20.7 Yes
4 (41) DF508/Unknown 27 21.1 Yes
Prucalopride was well tolerated. Patient 1 developed diarrhoea on initiating treatment
which spontaneously resolved. Patient 3 reported a headache that resolved within
14 days. Particular beneﬁt was noticed by Patients 1, 3 and 4. Patient 1 has reduced her
regular laxative therapy, has not required admission nor any additional laxatives since
starting treatment. Patient 2 reported minimal response. Patients 3 and 4 have reduced
their use of gastrografﬁn (Table 2).
Table 2. Treatment and clinical response
Pt Pre-prucalopride Prucalopride
Regular laxatives Additional laxatives in
last 12 months
Admissions,
constipation/
DIOS
Months of
prucalopride
in 2011
Additional laxatives Admissions,
constipation/
DIOS
1 Docusate
Lactulose Senna
N-Acetylcysteine
Klean prep ×2 courses
(variable dose)
Gastrografﬁn×10
(3 day course)
2 10 None. Senna
discontinued &
lactulose dose
decreased
0
2 Senna Lactulose
Movicol Domperidone
Gastrografﬁn ×2
(3 day course)
0 6 Picolax ×1 0
3 Senna Movicol
Docusate
Gastrografﬁn ×16
(3 day course)
0 3 Gastrografﬁn ×2
(3 day course)
0
4 Senna Movicol
Docusate
Gastrografﬁn weekly
(3 day course)
0 2 1 dose of gastrografﬁn
weekly
1
In this small number of patients prucalopride has provided symptomatic beneﬁt and
reduced the need for additional treatments.
230 Review of bowel preparation in adults with cystic ﬁbrosis
requiring colonoscopy
A. Matson1, J. Bunting1, S.C. Bell1. 1Prince Charles Hospital, Adult Cystic
Fibrosis Centre, Brisbane, Australia
An increased risk of gastrointestinal (GI) tract carcinoma has been reported in the
CF population. GI investigation necessitates patients with CF require a colonoscopy
procedure. Lack of adequate bowel preparation (prep) and the difﬁculty in cleansing
a “CF bowel” may result in misdiagnosis.
Objectives: To review the effectiveness of standard bowel prep versus CF speciﬁc
bowel prep for colonoscopy.
Methods: A retrospective chart audit was performed on CF patients with colon-
oscopy procedures performed from March 2000 to March 2011. Between March
2000 and October 2009 patients received standard bowel preparation, and from
October 2009 to March 2011 a CF speciﬁc bowel preparation was introduced.
Results: Sixty patients (53% male) had a colonscopy procedure between
March 2000 and March 2011. 55 total procedures were reviewed. Results indicated,
standard bowel prep provided effective clear out in 11 patients (32%) and CF speciﬁc
bowel prep provided effective clear out in 18 patients (86%). A Fisher’s Exact
statistical analysis demonstrated a signiﬁcant difference (p< 0.001), favouring effec-
tiveness of the CF speciﬁc bowel prep for colonoscopy. Results from colonoscopy
procedures identiﬁed colonic carcinoma in 3 (5.5%) patients and occurrence of
polyps in 14 (25%) patients.
Conclusions: Previous reports have highlighted a higher incidence and earlier age
of diagnosis of GI carcinoma in CF compared to the general population. The
introduction of a CF speciﬁc bowel prep has demonstrated a more effective cleanse,
to visualise the lower GI tract and assist investigation.
231 Helicobacter pylori infection in CF patients
L. Pop1, I. Ciuca1, Z. Popa2, S. Taban3, Z.L. Popa4, I. Popa1. 1University
of Medicine and Pharmacy Victor Babes, Pediatric II Department, Timisoara,
Romania; 2Cystic Fibrosis Centre, Timisoara, Romania; 3University of Medicine
and Pharmacy Victor Babes, Timisoara, Romania; 4University of Medicine and
Pharmacy Victor Babes, Obstretics and Gynecology Department, Timisoara,
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Objectives: The purpose of the work was the assessment of infection with
Helicobacter pylori (Hp) and adjacent pathology (ulcer, reﬂux esophagitis, ulcers)
in children and young people with CF, compared with those without CF.
Methods: Two study groups were considered for a transversal study. Group I
included 20 CF patients (9 male and 11 female), mean age 14.3 years and
group II − 24 patients (pts) with Hp infection (14 male and 10 female), median
age13.6 years. Selection criteria: presence of gastric symptoms. Quantitative detec-
tion of Hp antigen, esophagogastroduodenoscopy with histopathology examination
of gastric biopsy were performed. Gastritis were classiﬁed according to Sydney
criteria; Savary and Miller criteria were used for reﬂux esophagitis. All CF pts had
physiotherapy lying in special anti reﬂux positions.
Results: Half of CF patients had Hp infection associating chronic gastritis,
80% with nodular lesions. Esophagitis was diagnosed in 7 patients (70%). No
ulcer was found in CF patients nor in controls. In controls, 58.3% had Hp infection
with nodular gastritis in 13 cases (92.8%). 71.4% of controls presented esophagitis
lesions.
Conclusion: No signiﬁcant differences in the incidence of Hp infection in children
and young people with CF compared to controls with similar median age at
Hp infection and resemblance pathological features. In CF patients esophagitis
seems to be mainly linked to Hp infection and less related to physiotherapy position.
